Genmab and AbbVie Submit Applications for Lymphoma Drug Candidate

Genmab has submitted a Biologics License Application (BLA) to the FDA for epcoritamab for treatment of fast-growing forms of non-Hodgkin’s lymphoma.

An investigational antibody designed to simultaneously bind to and kill cancer cells, epcoritamab is being co-developed by AbbVie and Genmab under a collaboration deal inked in 2020.

The FDA application seeks approval for the treatment of adult patients with relapsed/drug-resistant large B-cell lymphoma after two or more lines of systemic therapy.

The European Medicines Agency (EMA) has accepted an application by AbbVie for epcoritamab for treating patients with relapsed/refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.